Processa Pharmaceuticals, Inc. (PCSA) stock
PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$1.70−0.03 (-1.73%)
Close on Nov 18, 2026Market cap $4.75MP/E –Yield –
Processa Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Processa Pharmaceuticals's operating income for the twelve months ending Dec 31, 2025 was -$13.99M. For fiscal 2025 it was -$13.99M. The highest annual figure on record is -$1.80M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.99M | – |
| FY2024 | Dec 31, 2024 | -$12.05M | – |
| FY2023 | Dec 31, 2023 | -$11.46M | – |
| FY2022 | Dec 31, 2022 | -$27.53M | – |
| FY2021 | Dec 31, 2021 | -$12.13M | – |
| FY2020 | Dec 31, 2020 | -$15.14M | – |
| FY2019 | Dec 31, 2019 | -$3.94M | – |
| FY2018 | Dec 31, 2018 | -$4.52M | – |
| FY2017 | Dec 31, 2017 | -$1.80M | – |
| FY2016 | Dec 31, 2016 | -$1.92M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.34M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.33M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.70M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.81M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.06M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.17M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.23M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.37M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.11M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.46M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.19M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.39M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.96M | – |
| Q2 FY2020 | Jun 30, 2020 | -$801.99K | – |
| Q1 FY2020 | Mar 31, 2020 | -$986.12K | – |
| Q4 FY2019 | Dec 31, 2019 | -$911.98K | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.00M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.14M | – |
| Q1 FY2019 | Mar 31, 2019 | -$882.52K | – |
| Q4 FY2018 | Dec 31, 2018 | -$741.95K | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.06M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.43M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.29M | – |
| Q4 FY2017 | Dec 31, 2017 | -$575.31K | – |
| Q1 FY2017 | Mar 31, 2017 | -$233.94K | – |
See a number that looks wrong?